BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 31662555)

  • 1. Association Between Radiation Tolerance of Lymphocytes and Clinical Outcomes in Cervical Cancer.
    Lee S; Cho O; Chun M; Chang SJ; Kong TW; Lee EJ; Lee Y
    In Vivo; 2019; 33(6):2191-2198. PubMed ID: 31662555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma.
    Cho O; Chun M; Oh YT; Noh OK; Chang SJ; Ryu HS; Lee EJ
    Tumour Biol; 2017 Oct; 39(10):1010428317733144. PubMed ID: 29022484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
    Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
    [No Abstract]   [Full Text] [Related]  

  • 5. The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer.
    Mizunuma M; Yokoyama Y; Futagami M; Aoki M; Takai Y; Mizunuma H
    Int J Clin Oncol; 2015 Oct; 20(5):989-96. PubMed ID: 25736530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy.
    Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
    Int J Clin Oncol; 2016 Aug; 21(4):741-747. PubMed ID: 26857458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy.
    Wu YF; Chu SC; Chang BS; Cheng YT; Wang TF
    Biomed Res Int; 2019; 2019():1263050. PubMed ID: 30834254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and benefit of concurrent chemoradiotherapy for elderly patients with uterine cervical cancer.
    Nosaka K; Shibata K; Utsumi F; Yoshida K; Niimi K; Sekiya R; Suzuki S; Kajiyama H; Kikkawa F
    Tumori; 2016 Dec; 102(6):600-605. PubMed ID: 27443893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematological parameters during concurrent chemoradiotherapy as potential prognosticators in patients with stage IIB cervical cancer.
    Cho O; Noh OK; Oh YT; Chang SJ; Ryu HS; Lee EJ; Chun M
    Tumour Biol; 2017 Feb; 39(2):1010428317694306. PubMed ID: 28222668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
    Seki T; Tanabe H; Nagata C; Suzuki J; Suzuki K; Takano H; Isonishi S; Ochiai K; Takakura S; Okamoto A
    Jpn J Clin Oncol; 2017 Jan; 47(1):32-38. PubMed ID: 27677664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
    Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy.
    Hu K; Wang W; Liu X; Meng Q; Zhang F
    Radiat Oncol; 2018 Dec; 13(1):249. PubMed ID: 30558636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcopenia Is Not a Prognostic Factor of Outcome in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy or Radiotherapy.
    Matsuoka H; Nakamura K; Matsubara Y; Ida N; Nishida T; Ogawa C; Katsi K; Kanazawa S; Masuyama H
    Anticancer Res; 2019 Feb; 39(2):933-939. PubMed ID: 30711978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI.
    Nam H; Park W; Huh SJ; Bae DS; Kim BG; Lee JH; Lee JW; Lim DH; Han Y; Park HC; Ahn YC
    Gynecol Oncol; 2007 Nov; 107(2):320-5. PubMed ID: 17675222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy.
    Zeng YC; Chi F; Xing R; Xue M; Wu LN; Tang MY; Wu R
    Jpn J Clin Oncol; 2016 Feb; 46(2):126-31. PubMed ID: 26611205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer.
    Cho O; Chun M; Chang SJ; Oh YT; Noh OK
    Anticancer Res; 2016 Jul; 36(7):3541-7. PubMed ID: 27354621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of stanniocalcin 2 is associated with tumor progression after radiotherapy in patients with cervical carcinoma.
    Shen XJ; Gu K; Shi JP; Yao JQ; Wu JC
    Int J Clin Exp Pathol; 2014; 7(12):8770-6. PubMed ID: 25674244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor growth patterns on magnetic resonance imaging and treatment outcomes in patients with locally advanced cervical cancer treated with definitive radiotherapy.
    Tsuruoka S; Kataoka M; Hamamoto Y; Tokumasu A; Uwatsu K; Kanzaki H; Takata N; Ishikawa H; Ouchi A; Mochizuki T
    Int J Clin Oncol; 2019 Sep; 24(9):1119-1128. PubMed ID: 31079257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of FDG PET metabolic tumour volume versus ADC histogram: prognostic value of tumour treatment response and survival in patients with locally advanced uterine cervical cancer.
    Ueno Y; Lisbona R; Tamada T; Alaref A; Sugimura K; Reinhold C
    Br J Radiol; 2017 Jul; 90(1075):20170035. PubMed ID: 28508679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.